Navigation Links
InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
Date:11/7/2012

hat the final procedural step for French pricing and reimbursement of Esbriet had been completed.  The company expects the commercial launch of Esbriet in France in the second half of November 2012. 
  • On October 2, 2012, InterMune announced that Health Canada had approved Esbriet for the treatment of mild to moderate IPF in adult patients.  IPF affects approximately 5,000 to 8,000 Canadians.  InterMune expects to make Esbriet available in Canada starting January 1, 2013 with a commercial organization of approximately 18 to 20 in Canada at the time of launch, including a field force of 10.  Approximately one-third of IPF patients in Canada are covered by private insurance and InterMune expects to secure coverage from substantially all of the private insurance plans in the first half of 2013.  Public (provincial) drug reimbursement plans cover approximately two-thirds of IPF patients and reimbursement from these plans is typically secured within 12 to 18 months of marketing approval.
  • InterMune today announced that the company secured Esbriet pricing and reimbursement in Belgium effective December 1, 2012 and plans to launch Esbriet there in early 2013. The Belgian annualized price of Esbriet is €30,240, or $36,533 at current exchange rates. 
  • InterMune has now concluded successful pricing and reimbursement discussions in nine European countries: Austria, Belgium, Denmark, France, Germany, Iceland, Luxembourg, Norway and Sweden.
  • InterMune today provided an update on the on-going pricing and reimbursement processes for Esbriet in the various European countries:
  • Italy – The company announced today that Esbriet successfully passed the Italian Technical-Scientific Commission review in October.  The company expects to conclude the pricing and reimbursement process in December of 2012 and plans to launch Esbriet in Italy as soon as possible after the process is successfully conc
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune To Release Third Quarter Financial Results On November 7
    2. InterMune To Present At JMP Securities Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune to Present at J. P. Morgan Healthcare Conference
    5. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
    6. PharmAthene Reports Third Quarter 2012 Financial Results
    7. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
    8. Patient Safety Technologies Reports Third Quarter 2012 Results
    9. PDI Reports 2012 Third Quarter Financial Results
    10. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    11. Neurocrine Biosciences Reports Third Quarter 2012 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/2/2015)... , June 2, 2015   Y-Prime, ... attending the BIO Exhibition 2015 in ... the world,s largest biotechnology gathering, allows influential decision ... executives, where they can evaluate emerging technologies such ... eClinical expertise in the design, implementation and management ...
    (Date:6/2/2015)... June 2, 2015   BioClinica ® , Inc., ... today announced that David Peters , an accomplished ... Vice President and Chief Financial Officer (CFO) and will ... Peters brings more than 25 years of financial and ... has extensive and deep knowledge in all areas of ...
    (Date:6/2/2015)... , June 2, 2015   Sigma-Aldrich Corporation ... and Technology company, announced today it has entered ... to launch genetically engineered human neural differentiated cells ... research of neurological diseases. These new products, in ... and versatile tools for the study of central ...
    (Date:6/2/2015)... June 2, 2015 /PRNewswire/ -- China Cord Blood Corporation (NYSE: ... China,s leading provider of cord blood collection, ... services, today announced that the Special Committee of the Company,s ... Lokey ( China ) Limited as its ... LLP as its United States legal ...
    Breaking Biology Technology:YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2BioClinica Names David Peters New Chief Financial Officer 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 3China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 3
    ... ... ... 2010 -- ProRepro today announced it has become an Autodesk authorized value-added reseller (VAR). ... Southern California. ProRepro’s qualified staff demonstrates in-depth technical and industry knowledge and a commitment ...
    ... INDIANAPOLIS and WALTHAM, Mass. , May 6, 2010 ... Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ALKS ... classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a ... (PDUFA) action date of October 22, 2010 . , ...
    ... May 6 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. ( ... company specialized in oncology and endocrinology, today announced that ... Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted ... is currently in a Phase 2 trial in advanced ...
    Cached Biology Technology:ProRepro Becomes a Value-Added Reseller for Autodesk 2BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 2BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 3BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 4BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 5BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 6BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 7BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 8Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 2Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 3
    (Date:5/21/2015)... The Sync Project™ , a global collaboration harnessing ... a collaborative partnership with Berklee,s Institute for Creative ... on original research, joint course development and an internship ... Sync Project and BerkleeICE are exploring the launch of ... academic year.  The course will focus ...
    (Date:5/19/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
    (Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
    Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
    ... University of Texas at San Antonio will bring together ... countries when it hosts the inaugural UTSA North American ... Building at the UTSA Downtown Campus. The summit will ... Canada and Mexico addressing the energy needs for future ...
    ... A novel cell therapy using retinal pigment epithelial ... implanted in the brain can improve the symptoms ... (PD). Rush University Medical Center neurosurgeon Dr. ... University, Atlanta found the therapy Spheramine was well-tolerated ...
    ... safer along Massachusetts Bay,s busy shipping lanes this spring, ... buoys recognize whales, distinctive calls and route the information ... system, giving ships the chance to avoid deadly collisions. ... >) -- developed at the Cornell Lab of Ornithology ...
    Cached Biology News:UTSA hosts North American Energy Summit May 1-2 2Cell-based therapy shows promise in patients with Parkinson's disease 2Cell-based therapy shows promise in patients with Parkinson's disease 3Warning buoys for right whales installed along Massachusetts Bay 2
    ... Immobilized] Goat Immunogen: Goats ... (MASMTGGQQMG). Antibody was isolated by affinity ... support. Goat anti- human T7 affinity purified ... cyanogens bromide method. Specificity: ...
    C/EBPdelta Antibody Shipping Temperature: Cold Storage Temperature: -20C...
    Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
    Anti-human C5a/C5a des-Arg (neo-epitode), Clone 2952, Monoclonal Antibody...
    Biology Products: